Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis : serum inflammatory biomarkers, clinical efficacy,and microbiological eradication by F. Blasi et al.
© 2013 Blasi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2013:9 55–64
Therapeutics and Clinical Risk Management
Cefditoren versus levofloxacin in patients  
with exacerbations of chronic bronchitis: serum 
inflammatory biomarkers, clinical efficacy,  
and microbiological eradication
Francesco Blasi
Paolo Tarsia
Marco Mantero
Letizia C Morlacchi
Federico Piffer
Department of Pathophysiology 
and Transplantation, University of 
Milan, IRCCS Fondazione Cà Granda 
Ospedale Maggiore Policlinico, 
Milan, Italy
Correspondence: Francesco Blasi 
Department of Pathophysiology and 
Transplantation, University of Milan, 
IRCCS Fondazione Cà Granda Ospedale 
Via F. SForza 35 20122, Maggiore 
Policlinico, Milan, Italy 
Tel +39 02 5032 0627 
Fax +39 02 5032 0625 
Email francesco.blasi@unimi.it
Background: The aim of this open-label, randomized, parallel-group pilot study was to evaluate 
the efficacy of cefditoren pivoxil and levofloxacin in terms of speed of reduction in inflammatory 
parameters, clinical recovery, and microbiological eradication.
Methods: Forty eligible patients with acute exacerbation of chronic bronchitis (AECB) were 
randomized to receive cefditoren 200 mg twice a day for 5 days (n = 20) or levofloxacin 500 mg 
once daily for 7 days (n = 20).
Results: The inflammatory parameters which were significantly reduced at test-of-cure with 
respect to visit 1 were Krebs von den Lundgen-6 (KL-6) and interleukin-6. KL-6 decreased 
both in the overall study population (from 19 ± 11 UI/mL to 6 ± 8 UI/mL, P = 0.000) 
and in the cefditoren (from 19 ± 13 UI/mL to 8 ± 10 UI/mL, P = 0.006) and levofloxacin 
(from 19 ± 10 UI/mL to 5 ± 5 UI/mL, P = 0.000) arms. Similarly, interleukin-6 decreased both in 
the overall study population (from 13.35 ± 16.41 pg/mL to 3 ± 4.7 pg/mL, P = 0.000) and in the 
cefditoren (from 15.90 ± 19.54 pg/mL to 4.13 ± 6.42 pg/mL, P = 0.015) and levofloxacin (from 
10.80 ± 12.55 pg/mL to 1.87 ± 1.16 pg/mL, P = 0.003) arms. At the end of treatment (test-of-cure, 
6–9 days after drug initiation), the clinical success rate in the overall study population was 78%; 
the clinical cure rate was 80% in the cefditoren arm and 75% in the levofloxacin arm. Globally, 
bacteriological eradication at test-of-cure was obtained in 85% of the overall study population. 
Both treatments were well tolerated.
Conclusion: Cefditoren represents a valid option in the treatment of mild to moderately 
severe cases of AECB in the outpatient care setting. Moreover, the use of this cephalosporin 
is associated with a significant reduction of interleukin-6 and KL-6, two key mediators of lung 
inflammation and epithelial damage.
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acute exacerbations
Introduction
Chronic respiratory diseases like chronic bronchitis and chronic obstructive 
pulmonary disease (COPD) place a huge burden on economic resources and on 
health care systems.1–3 Acute exacerbation of chronic bronchitis (AECB) represents 
a major public health concern and causes significant morbidity and mortality in these 
patients, contributing to a long-term decline in lung function and increasing the risk 
of cardiovascular events.4–9 It is estimated that up to 50%–80% of AECBs are caused 
by bacterial infections which may respond to antimicrobial therapy.10–13
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Inflammation also plays a central role in the pathogenesis 
of AECB.14–16 More specifically, if bacteria are thought to 
be the trigger for AECB, a neutrophilic inflammation would 
be expected as a response to the acute infection. Sethi et al 
showed that increased airway inflammation, ie, higher levels 
of tumor necrosis factor alpha and interleukin (IL)-8, was 
associated with Haemophilus influenzae and Moraxella 
catarrhalis isolates in sputum, thus supporting an etiologic 
role for these pathogens in AECB.16 Cytokines titers/levels 
have often been used to describe inflammatory patterns in 
lung diseases, both in serum and respiratory tract/airway 
specimens, such as sputum or bronchoalveolar lavage fluid. 
Krebs von den Lundgen-6 (KL-6), instead, is a circulating 
mucin-like high molecular weight glycoprotein that is 
strongly expressed on type II pneumocytes and bronchiolar 
epithelial cells, and is a useful serum marker of epithelial 
damage in the lung.17 KL-6 is elevated in bronchoalveolar 
lavage fluid and in the serum of patients with different types 
of interstitial pneumonia, and is a useful serum marker in the 
management of pneumonia.17–19
AECB is usually classified based on severity. A significant 
number of individuals are affected by mild to moderately 
severe cases of AECB and can therefore be treated in 
an outpatient setting, with institution of an oral therapy, 
often decided by general practitioners.20 Given that at least 
half of AECBs are caused by bacterial infections, early 
institution of an adequate/appropriate antimicrobial regimen 
is crucial in order to ensure quick recovery. GOLD (Global 
Initiative for Chronic Obstructive Lung Disease) guidelines 
suggest the use of amoxicillin-clavulanic acid, advanced 
macrolides, and second-generation and third-generation 
cephalosporins for uncomplicated AECB, but the prevalence 
of macrolide resistance is increasing worldwide. Respiratory 
fluoroquinolones (levofloxacin, moxifloxacin) are a 
common choice for patients with severe airway obstruction, 
comorbidity, and/or recurrent exacerbations, but could be 
spared in less severe cases.11
Cephalosporins may be useful for the treatment of 
mild to moderately severe cases of AECB. Several studies 
have demonstrated both the effectiveness and safety of 
these drugs in this population, also in comparison with 
fluoroquinolones.21–25 Among the cephalosporins, cefditoren 
pivoxil, an oral, β-lactamase-stable, expanded-spectrum 
cephalosporin, was shown to have good in vitro activity 
not only against methicillin-susceptible Staphylococcus 
aureus, Streptococcus pyogenes, Streptococcus pneumoniae, 
including penicillin-resistant strains, but also against 
H. influenzae and M. catarrhalis,26–31 with minimum 
inhibitory concentrations of 90% for AECB isolates that 
are lower than those for other oral cephalosporins,22 and its 
clinical efficacy and safety have been well established.32–35 
In comparative studies with cephalosporins, levofloxacin 
was demonstrated to be more favorable in the treatment of 
AECB21,24,36 but, to the best of our knowledge, no trial has 
been conducted comparing cefditoren and levofloxacin.
The current study was designed to compare cefditoren 
and levofloxacin in order to assess their efficacy in terms 
of speed of reduction of inflammatory parameters, clinical 
recovery, and microbiological eradication.
Materials and methods
Study design
An open-label, randomized, levofloxacin-controlled, parallel-
group pilot study of cefditoren was performed from January 
2012 to April 2012 in the Respiratory Department, IRCCS 
Fondazione Ca’ Granda Ospedale Maggiore Policlinico, 
Milan, Italy. The protocol was approved by the ethics 
committee of the participating center (EudraCT 2011-
000531-88, ClinicalTrial.gov identifier NCT01467297). 
All patients gave written informed consent prior to 
study entry.
Patient selection
All outpatients aged 40–75 years with a diagnosis of 
chronic bronchitis (defined as history of cough, excessive 
mucus secretion, and production of sputum on most days 
over at least three consecutive months for more than two 
successive years), an acute exacerbation (characterized by 
the presence of three symptoms or at least two symptoms, 
including purulence, increased dyspnea, increased sputum 
volume, increased sputum purulence) and a valid sputum 
specimen from the lower airways for microbiological 
evaluation (,10 squamous epithelial cells and .25 
polymorph nuclear leukocytes per low power magnification 
100 × field) were screened. Patients with hypersensitivity/
allergy to any component of the study medications, 
underlying asthma, systemic corticosteroids, pregnancy, 
history of tendinopathy, psychiatric disease, epilepsy, 
recent cardiovascular disease, forced expiratory volume 
in one second (FEV
1
) ,50%, any electrocardiographic 
abnormalities, any chest x-ray abnormalities, deficient 
glucose-6-phosphatase dehydrogenase activity, hepatic 
failure, renal failure, lower respiratory tract illness other than 
chronic bronchitis or COPD, concurrent infections and/or 
neoplasm, concurrent treatment with hypoglycemic drugs, 
fenbrufen or xanthines, treatment with antibiotics within the 
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previous week, or treatment with experimental drugs in the 
previous 4 weeks were excluded.
Treatment
Patients who fulfilled all the inclusion and none of the exclusion 
criteria were randomized (1:1) to receive cefditoren 200 mg 
twice a day for 5 days or levofloxacin 500 mg once daily for 
7 days, according to the manufacturer’s indications.
Clinical assessment
Patients were examined at the time of study enrolment (visit 
1 on day 1 of treatment), and evaluations were performed 
during treatment (visit 2, days 2–4), at the end of treatment 
(visit 3, test-of-cure visit, days 6–9), and at follow-up 
(visit 4, late post therapy assessment, days 28–30). At 
visit 1, inclusion/exclusion criteria, age, gender, underlying 
comorbidities, randomization number, medical history, 
physical examination, vital signs, pregnancy test in urine 
(for females in child-bearing age), electrocardiogram, 
and chest x-rays were assessed, and a sputum sample was 
obtained by expectoration and forwarded to the laboratory 
for microscopic examination, Gram staining, and culture of 
valid specimens for pathogen identification. At all visits, 
the following variables were evaluated by the investigator: 
physical examination, vital signs, dyspnea (0, absent; 
1, mild; 2, moderate; 3, severe), cough (0, absent; 1, mild, 
morning only; 2, moderate, night and day, but not disturbing 
sleep; 3, severe, disturbing sleep), fever . 37.5°C (0, absent; 
1, present), sputum purulence (0, mucoid, white to gray; 
1, mucopurulence, yellowish; 2, purulence, greenish; 3, severe, 
brownish), sputum volume (0, absent; 1, mild; 2, moderate; 
3, severe), lung function test (FEV
1
, FVC [forced vital 
capacity]), microbiological assessment (if a sputum specimen 
was available) and occurrence of adverse events. Blood 
samples were collected for analysis of biomarkers (KL-6, 
cytokines) at visit 1, 2 and 3, and for laboratory tests at visit 
1 and 3. Clinical and microbiological data and biomarkers 
were compared at visits 2 and 3 with those present at baseline 
to evaluate clinical response; a further microbiological 
assessment (in case of clinical worsening) was performed at 
visit 4. A standardized case report form was used to record 
patient characteristics.
Titration of cytokines
The Evidence Investigator™ cytokine and growth factors 
high sensitivity array with Randox biochip technology (solid-
state device containing an array of discrete test regions of 
immobilized antibodies specific to different cytokines and 
growth factors) was used for the simultaneous quantitative 
detection of multiple related immunoassays from a single 
sample. A sandwich chemiluminescent immunoassay was 
used for the cytokine array. Increased cytokine levels in a 
clinical specimen leads to increased binding of antibody 
labeled with horseradish peroxidase and an increase in the 
chemiluminescence signal emitted. The light signal generated 
from each of the test regions on the biochip is detected using 
digital imaging technology and compared with that from a 
stored calibration curve. The concentration of analyte present 
in the sample was calculated from the calibration curve.
KL-6 determination
A human KL-6 enzyme-linked immunosorbent assay kit 
can be used for in vitro quantitative determination of human 
KL-6 concentrations in serum, plasma, and other biological 
fluids. The microtiter plate provided in the kit is precoated 
with an antibody specific to KL-6. Standards or samples were 
added to the appropriate microtiter plate wells with a biotin-
conjugated polyclonal antibody preparation specific for 
KL-6, and avidin conjugated with horseradish peroxidase was 
added to each microplate well and incubated. A tetramethyl-
benzidine substrate solution was added to each well. Only 
wells containing KL-6, biotin-conjugated antibody, and 
enzyme-conjugated avidin showed a change in color. The 
enzyme-substrate reaction was terminated by addition of a 
sulfuric acid solution and the color change was measured 
spectrophotometrically at a wavelength of 450 ± 2 nm. The 
concentration of KL-6 in the samples was determined by 
comparing the OD of the samples with the standard curve.
Efficacy evaluation
The clinical score was calculated by adding the single scores 
of the semiquantitative scales of dyspnea, cough, fever, 
sputum purulence, and sputum volume. The total scores 
obtained at visit 2 and visit 3 (test-of-cure) were compared 
with those obtained at visit 1. Clinical efficacy, evaluated at 
visit 2 and 3, was defined as cure (disappearance of all signs 
and symptoms of AECB reported at visit 1, or reduction of 
at least 3 points on the total score calculated at visit 1 and no 
further antibiotic therapy required) or failure (worsening of 
at least one sign and symptom of AECB reported at visit 1, 
or no change, increase, or reduction of ,3 points on the total 
score calculated at visit 1, or additional antimicrobial therapy 
required). Bacteriological efficacy, evaluated at visit 2 and 3, 
was defined as eradication (original causative organism absent 
on sputum culture), persistence (original organism still 
present on sputum culture), superinfection (isolation of new 
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organism judged to be causing an infectious process in the 
respiratory tract associated with clinical signs), presumed 
eradication (absence of appropriate culture material for 
evaluation because the patient improved clinically and was 
unable to produce sputum), presumed persistence (absence of 
appropriate culture material for evaluation and patient assessed 
as clinical failure), or indeterminate (bacteriological response 
of the study drug not evaluable for any other reason). At the 
follow-up visits, in cases where a worsening of key signs and 
symptoms was observed, bacteriological efficacy was defined 
as relapse (presence of the original causative organism in 
the sputum), eradication with reinfection (elimination of the 
initial causative organism followed by replacement with new 
species), or not evaluable.
Statistical analysis
Baseline characteristics of the population and biomarkers levels 
on visits 1, 2, and 3 were considered for statistical analysis. 
Continuous data were expressed as the mean ± standard 
deviation and compared using the unpaired Student’s 
t-test. Categorical data were expressed as the number and 
percentage of events and compared using Fisher’s exact test. 
In all the comparisons, a P value , 0.05 was considered to 
be statistically significant. The data were analyzed using the 
Statistical Package for Social Sciences version 18.0 (SPSS 
Inc, Chicago, IL, USA) for MAC OS.
Results
Patient demographics
A total of 40 patients (median age 63 ± 7 years) were enrolled 
in the study. Twenty patients were assigned to the cefditoren 
arm and 20 patients to the levofloxacin arm. Demographic 
characteristics, concomitant diseases, and baseline FEV
1
 
values and blood oxygen saturation are shown in Table 1. 
There were no differences in baseline characteristics between 
the two treatment groups; all patients were either smokers 
or ex-smokers. Causative pathogen(s) were isolated in 
29 patients (72.5%), comprising 15 treated with cefditoren 
and 14 treated with levofloxacin. The most frequently isolated 
pathogens were H. influenzae (n = 19), S. pneumoniae (n = 6), 
and M. catarrhalis (n = 2); infection was caused by multiple 
pathogens in two cases (S. pneumoniae plus M. catarrhalis, 
n = 1; H. influenzae plus M. catarrhalis, n = 1).
Inflammatory parameters
Table 2 lists the inflammatory parameters evaluated at visit 1 
and at test-of-cure (visit 3). In general terms, there were no 
significant differences between groups both at visit 1 and the 
test-of-cure visit for any of the parameters, except for IL-4 
(visit 1 and test-of-cure), interferon gamma (visit 1), and 
KL-6 (test-of-cure). The inflammatory parameters which were 
significantly reduced at test-of-cure with respect to visit 1 
were KL-6 and IL-6. KL-6 decreased in the overall study 
population (from 19 ± 11 UI/mL to 6 ± 8 UI/mL, P = 0.000) 
and in the cefditoren (from 19 ± 13 UI/mL to 8 ± 10 UI/mL, 
P = 0.006) and levofloxacin (from 19 ± 10 UI/mL to 
5 ± 5 UI/mL, P = 0.000) arms. Similarly, IL-6 decreased both 
in the overall study population (from 13.35 ± 16.41 pg/mL 
to 3 ± 4.7 pg/mL, P = 0.000) and in the cefditoren (from 
15.90 ± 19.54 pg/mL to 4.13 ± 6.42 pg/mL, P = 0.015) and 
levofloxacin (from 10.80 ± 12.55 pg/mL to 1.87 ± 1.16 pg/mL, 
P = 0.003) arms (Figure 1A and B). C-reactive protein levels 
showed a similar pattern (Figure 1C). The delta values for 
reduction of KL-6 and IL-6 were similar for the overall 
study population, cefditoren arm, and levofloxacin arm, 
with no statistically significant differences between groups 
(Table 3).
Clinical and bacteriological response
The clinical score, calculated based on the single scores 
of dyspnea, cough, fever, sputum purulence, and sputum 
volume, decreased progressively during the study, both in 
Table 1 Baseline characteristics of the study population
Overall study population 
(n = 40)
Group 1 – cefditoren 
(n = 20)
Group 2 – levofloxacin 
(n = 20)
P
Female, n (%) 14 (35) 9 (45) 5 (25) 0.320
AGE, years (SD) 63 ± 7 65 ± 7 62 ± 7 0.183
Cardiovascular disease, n (%) 7 (18) 3 (15) 4 (20) 1.000
GERD, n (%) 5 (13) 3 (15) 2 (10) 1.000
Diabetes, n (%) 4 (10) 1 (5) 3 (15) 0.605
FEV1 %, mean (SD) 76 ± 12 76 ± 14 75 ± 8 0.783
SpO2 %, mean (SD) 95 ± 1 95 ± 1 94 ± 1
Abbreviations: GERD, Gastroesophageal reflux disease; FEV1, Forced Expiratory Volume in 1 second; SpO2, blood oxygen saturation; SD, standard deviation.
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the overall study population (from 6.48 ± 1.59 at visit 1 
to 2.05 ± 1.62 at test-of-cure, P = 0.000) and in the cefdi-
toren (from 6 ± 1.59 at visit 1 to 2.30 ± 1.75 at test-of-
cure, P = 0.000) and levofloxacin (from 6.95 ± 1.47 at 
visit 1 to 1.80 ± 1.47 at test-of-cure, P = 0.000) arms 
(Figure 2). Differences between groups were not statisti-
cally significant.
At the end of treatment (test-of-cure, 6–9 days after 
drug initiation), the clinical success rate in the overall 
study population was 78%, and the clinical cure was simi-
lar in both study groups (80% and 75% in the cefditoren 
and levofloxacin arms, respectively, Figure 3). Globally, 
bacteriological eradication at test-of-cure was obtained in 
85% of the overall study population; eradication rate was 
higher in the levofloxacin arm compared with the cefditoren 
arm (95% versus 75%), although the difference was not 
statistically significant.
Safety
Four patients in the levofloxacin arm and two patients in the 
cefditoren arm reported gastrointestinal side effects (either 
mild nausea or diarrhea).
Discussion
COPD is characterized by an abnormal inflammatory 
response which extends beyond the lungs, with evidence 
of low-grade systemic inflammation. Increased levels of 
acute phase proteins such as proinflammatory cytokines, 
including IL-6, were found in the circulation of patients 
with stable COPD, and have been shown to be associated 
Table 2 Inflammatory biomarkers on visit 1 and on test of cure (TOC) in the overall study population and in the study groups
Biomarker Overall study population  
(n = 40)
Group 1 – cefditoren  
(n = 20)
Group 2 – Levofloxacin  
(n = 20)
P
VISIT 1
KL6, UI/mL 19 ± 11 19 ± 13 19 ± 10 0.849
IL2 3.04 ± 2.77 3.28 ± 3.11 2.80 ± 2.44 0.586
IL4 1.99 ± 1.57 1.39 ± 1.36 2.60 ± 1.56 0.013
IL6 13.35 ± 16.42 15.90 ± 19.54 10.80 ± 12.55 0.332
IL8 17.00 ± 26.48 17.09 ± 25.70 16.91 ± 27.90 0.983
IL10 3.04 ± 9.72 1.53 ± 1.65 4.56 ± 13.65 0.331
VEGF 133.75 ± 199.63 152.07 ± 211.32 115.44 ± 190.90 0.568
IFnβ 1.44 ± 2.08 2.14 ± 2.63 0.75 ± 0.96 0.032
TnFα 4.41 ± 2.26 4.54 ± 2.54 4.28 ± 2.00 0.722
IL1α 0.39 ± 0.52 0.35 ± 0.49 0.43 ± 0.56 0.653
IL1β 1.63 ± 1.17 1.73 ± 1.29 1.54 ± 1.07 0.617
MCP1 228.53 ± 170.58 254.38 ± 210.72 202.67 ± 117.98 0.344
EGF 46.29 ± 87.87 49.89 ± 80.87 47.70 ± 96.46 0.921
TOC
KL6, UI/mL 6 ± 8a 8 ± 10a 5 ± 5a 0.016
IL2 4.79 ± 8.35 6.71 ± 11.23 2.87 ± 3.00 0.147
IL4 2.07 ± 1.37 1.55 ± 1.20 2.58 ± 1.37 0.016
IL6 3.00 ± 4.70a 4.13 ± 6.42a 1.87 ± 1.16a 0.130
IL8 14.29 ± 20.93 12.09 ± 17.68 16.48 ± 24.01 0.514
IL10 11.69 ± 63.91 2.15 ± 1.89 21.24 ± 90.49 0.351
VEGF 112.53 ± 147.90 116.97 ± 166.16 108.09 ± 131.35 0.852
IFnγ 4.40 ± 11.03 3.36 ± 6.95 5.44 ± 14.11 0.558
TnFα 9.39 ± 17.64 13.25 ± 24.32 5.53 ± 3.93 0.169
IL1α 0.50 ± 0.66 0.55 ± 0.69 0.44 ± 0.64 0.605
IL1β 1.19 ± 1.01 1.31 ± 1.08 1.06 ± 0.93 0.436
MCP1 234.20 ± 156.77 248.08 ± 181.61 220.31 ± 130.62 0.582
EGF 54.48 ± 93.46 59.33 ± 104.67 46.63 ± 83.21 0.747
Notes: aP , 0.05 TOC vs visit 1. Levels of biomarkers are expressed as pg/mL, unless otherwise indicated. All data are expressed as Mean ± SD; Group 1 and Group 2 were 
compared using the unpaired Student t-test. P values # 0.05 were considered significan. TOC is 6–9 days after the drug initiation, at the end of treatment.
Abbreviations: KL-6, Krebs von den Lundgen-6; IL-2, interleukin 2; IL-4, interleukin 4; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; VEGF, Vascular Endothelial 
Growth Factor; IFN, Interferon; TNFα, Tumor Necrosis factor alpha; IL1α, interleukin 1 alpha; IL1β, interleukin 1 beta; MCP1, Monocyte Chemoattractant Protein 1; 
EGF, Epidermal Growth Factor; TOC, test of cure.
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with impaired functional capacity, reduced daily physical 
activity, and decreased health status.37 IL-6 is now emerging 
as a potentially pivotal player in the pathogenesis of lung 
disease. Further, in the lung, IL-6 dissociates from other 
inflammatory markers and could be a target for treatment 
of asthma, COPD, or other pulmonary diseases.38 A recent 
study by Grubek-Jaworska et al, which sought a relation-
ship between IL-6 and IL-13 concentrations in induced 
sputum and respiratory function of patients with COPD or 
asthma, showed a negative correlation between IL-6 level, 
but not IL-13 level, and respiratory disorders, determined 
by a temporal decay in FEV
1
 and FVC in COPD patients.39 
Two recently published studies of inflammatory biomark-
ers in patients with COPD showed that elevated IL-6 serum 
levels, but not tumor necrosis factor alpha or IL-8 levels, are 
predictive of increased mortality, and are associated with 
poor clinical outcomes.40,41 Moreover, acute exacerbations 
of chronic obstructive pulmonary disease are associated 
with elevations of plasma fibrinogen and serum IL-6 levels.42 
Our results show that both cefditoren and levofloxacin are 
effective in decreasing inflammatory biomarkers in AECB. 
Serum IL-6 levels were significantly different between 
visit 1 and test-of-cure, and the reduction was similar in the 
cefditoren and levofloxacin groups (11.76 ± 14.07 pg/mL 
and 8.93 ± 12.23 pg/mL, respectively).
Our results show that both cefditoren and levofloxacin 
are also significantly effective in decreasing KL-6 baseline 
levels in AECB (delta value between visit 1 and test-of-
cure was 10.53 ± 10.84 UI/mL and 14.73 ± 10.99 UI/mL, 
respectively; difference not statistically significant). KL-6 
has already been described as a useful serum marker of lung 
epithelial damage. In fact, KL-6 is elevated in the plasma and 
bronchoalveolar lavage fluid of patients with acute respiratory 
distress syndrome. Plasma levels of KL-6 reflect the severity 
of lung injury and show that bronchoalveolar lavage fluid lev-
els correlate with indices of inflammation.43 Elevated levels 
of KL-6 in plasma and epithelial lining fluid may provide 
a useful marker for acute respiratory distress syndrome in 
ventilated patients and have a possible negative prognostic 
significance.44,45 Extensive investigations showed that serum 
KL-6 is elevated in 70%–100% of patients with various 
interstitial lung diseases (idiopathic interstitial pneumonias, 
collagen vascular disease-associated interstitial pneumonia, 
hypersensitivity pneumonia, radiation pneumonitis, drug-
induced interstitial lung diseases, acute respiratory distress 
syndrome, pulmonary sarcoidosis, and pulmonary alveolar 
proteinosis) and support its utility both as a serum biomarker 
for detecting the presence of disease and as an index of 
disease activity.19,46 KL-6 is currently one of the best and 
most reliable serum biomarkers available for management of 
interstitial lung disease.19 In these cases, initial elevated serum 
KL-6 levels can identify patients at increased risk for subse-
quent mortality.47,48 Furthermore, Ishikawa et al demonstrated 
that aging and long-term smoking lead to an increase in KL-6 
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Figure 1 Levels of KL6 (A) and IL6 (B) and C-reactive protein (C), cefditoren and levofloxacin arms at visit 1, 2 and TOC.
Note: *P = 0.05 TOC vs visit 1.
Abbreviations: TOC, test of cure; KL-6, Krebs von den Lundgen-6; IL-6, interleukin 6; CRP, C-reactive protein.
Table 3 Speed of reduction of inflammatory biomarkers
ΔBiomarker Overall study 
population
Group 1 – 
cefditoren
Group 2 – 
levofloxacin
P
ΔKL6, UI/mL 12.63 ± 10.98 10.53 ± 10.84 14.73 ± 10.99 0.231
ΔIL6, pg/mL 10.36 ± 13.09 11.76 ± 14.07  8.93 ± 12.23 0.499
Notes: Comparison between treatments was performed at TOC. Variations (Δ) 
between visit 1 and TOC were calculated for each parameter. All Δs are expressed 
as Mean ± SD. Group 1 and Group 2 were compared using the unpaired Student’s 
t-test. P values # 0.05 were considered significant. TOC is 6–9 days after the drug 
initiation, at the end of treatment.
Abbreviations: IL-6, interleukin 6; KL-6, Krebs von den Lundgen-6; TOC, test 
of cure.
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levels in the lung, induced sputum, and plasma.49 A recently 
published study showed that both KL-6 and surfactant protein 
D, and particularly the product of surfactant protein D and 
KL-6, are good indicators of the presence of fibrotic lesions 
in the lungs of patients with combined pulmonary fibrosis 
and emphysema.17 Finally, levels of surfactant proteins A and 
D and KL-6 are elevated in the induced sputum of patients 
with COPD.50 To the best of our knowledge, no other trial 
comparing levofloxacin and cephalosporins has focused on 
KL-6; in general, no studies have evaluated KL-6 in AECB. 
Our results confirm that although levofloxacin is associated 
with a more rapid reduction in KL-6 levels, treatment with 
cefditoren is also associated with a decrease in KL-6 levels. 
These patterns of response were also confirmed by analysis 
of C-reactive protein levels across time.
The effect of the treatments on inflammation is probably 
related to their antibacterial efficacy, even if immunomodulation/ 
anti-inflammatory properties of the two antibiotics cannot be 
ruled out. Both cefditoren and levofloxacin showed very good 
clinical efficacy (75%–80%). Levofloxacin offered a quicker 
rate of symptom resolution at visit 2, but at test-of-cure, all 
patients treated with cefditoren recovered fully. The clinical 
value of cefditoren in AECB has been demonstrated previously 
by other clinical studies.22,51 The clinical efficacy of these trials 
was in line with that observed in our study. Other random-
ized studies compared levofloxacin 500 mg once daily with 
cephalosporins, especially cefuroxime 250 mg twice daily in 
patients with AECB. Generally, the clinical cure rates were 
higher in the levofloxacin group.21,24,36
Antimicrobial prescribing should aim to eradicate or 
maximally reduce the pathogen bacterial load. In our study, 
the microbiological data were consistent with traditional find-
ings in AECB; in particular, isolates from sputum on visit 1 
are similar to those of other studies.16,22,52 Both antibiotics 
showed good activity against the microorganisms isolated.
Cefditoren was very well tolerated. Only a few adverse 
events were reported in our study and did not cause treat-
ment discontinuation. Moreover, cefditoren had an adverse 
event profile comparable with that of other cephalosporins 
(gastrointestinal system disorders being the most frequently 
reported adverse events).21,22
In an era characterized by a limited number of new anti-
biotics in the pipeline, and overuse and misuse of current 
antibiotics, appropriate selection of available antimicrobial 
agents can reduce treatment failures (and subsequently health 
care costs) and help to prevent the spread of resistant bacterial 
strains. In 2005, the Council for Appropriate and Rational 
Antibiotic Therapy (CARAT), an independent and multi-
disciplinary panel of health care professionals, clinicians, 
and scientists, developed criteria to guide appropriate and 
accurate antibiotic selection aimed at optimizing antibiotic 
therapy. These criteria are evidence-based results, therapeutic 
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benefits, safety, optimal drug for the optimal duration, and 
cost-effectiveness.53 Martinez et al used CARAT criteria for 
choosing the optimal drug at its optimal dose and duration 
for antimicrobial treatment in outpatients with AECB due 
to bacterial infection. Patients were stratified according to 
risk factors to improve selection of targeted antimicrobial 
therapy. In chronic bronchitis without risk factors (simple), 
the first-line drugs are second-generation macrolides, second-
generation or third-generation cephalosporins, amoxicil-
lin, doxycycline, or cotrimoxazole; fluoroquinolones are 
recommended as first-line therapy for patients with chronic 
bronchitis who have risk factors.54 Recently, the appropriate 
and accurate use of antibiotics has been emphasized by Inter-
national and National Scientific Society, including the Italian 
Society of Chemotherapy.55 In 2011, a multinational work-
ing group on antibiotic stewardship from the International 
Society of Chemotherapy put together ten recommendations 
for physicians prescribing antibiotics for outpatients. The 
first two recommendations are strictly linked to appropri-
ate use, ie, use antibiotics only when needed and select the 
appropriate antibiotic.56
Canut et al used a probability (therapeutic outcomes) model 
to predict the likelihood of clinical success with particular 
antimicrobial agents in the treatment of patients with AECB. 
According to this model, fluoroquinolones (levofloxacin, 
ciprofloxacin, moxifloxacin), cefditoren, and amoxicillin-
clavulanate are the most appropriate antibiotics for treatment 
of patients with AECB in terms of predicted clinical efficacy.57 
In our study, cefditoren was shown to be therapeutically 
comparable with levofloxacin in terms of efficacy and safety 
for management of cases of AECB. Although levofloxacin 
had excellent activity in almost all cases, oral cephalosporins 
should be considered for less severely unwell patients and 
uncomplicated AECB, as recommended by some Italian sci-
entific groups (Federazione delle Associazioni dei Dirigenti 
Ospedalieri Internisti; Gruppo Italiano per lo Studio delle 
Antibiotico Resistenze nelle Infezioni Respiratorie), reserving 
fluoroquinolones for more severe cases (moderate to severe 
AECB with or without risk factors for multiresistant patho-
gens) or for intolerance to beta-lactams/macrolides or treatment 
failure (second-line therapy).20,58 Another point to consider in 
the choice of the appropriate antibiotic for AECB is safety. 
Cardiac alterations,59,60 blood glucose impairment,59 hepatic 
injury,61 and ocular events (such as retinal detachment62) have 
been reported with fluoroquinolones, especially in patients 
with predisposing factors, such as diabetes and heart disease.59 
In addition, because of physiological changes in renal func-
tion and when certain comorbidities are present, some special 
considerations are necessary when elderly patients are treated 
with these drugs.63 For this reason, Lode et al, evaluating the 
safety and tolerability of oral antibiotics commonly prescribed 
for respiratory tract infections, devote considerable attention 
to the fluoroquinolone agents.64 According to the recently 
published European Respiratory Society guidelines on lower 
respiratory infections, fluoroquinolones are highly active and 
efficacious against respiratory pathogens and should be used 
in well defined circumstances. If the prevalence of first-step 
mutants is low, use of the most potent fluoroquinolones is a 
logical choice if resistance has to be avoided/delayed.65
To the best of our knowledge, this is the first study com-
paring levofloxacin and cefditoren in the treatment of AECB. 
The most important strength of our study is the assessment 
of the airway inflammatory pattern. We did not just describe 
outcomes, but we also examined inflammation and lung dam-
age during an acute infection. Assessment of the inflammatory 
pattern should also be extended to distal airways specimens, 
like sputum or possibly exhaled breath condensate. Further 
studies are needed to understand better the potential role played 
by oral cephalosporins in the management of AECB.
Conclusion
Cefditoren represents a valid option in the treatment of mild 
to moderately severe cases of AECB in the outpatient care 
setting. In this study, cefditoren showed very good clinical 
efficacy and activity against the microorganisms isolated. 
Moreover, use of this cephalosporin was associated with a 
significant reduction of IL-6 and KL-6, two key mediators 
of lung inflammation and epithelial damage.
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